We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




B-Type Natriuretic Peptide Sandwich Immunoassay Evaluated

By LabMedica International staff writers
Posted on 23 Apr 2019
Print article
Image: The Minicare I-20 handheld diagnostics platform is designed to detect multiple target molecules at very low concentrations in a single ‘finger-prick’ blood sample, and display the results on a handheld analyzer within minutes (Photo courtesy of Philips Healthcare).
Image: The Minicare I-20 handheld diagnostics platform is designed to detect multiple target molecules at very low concentrations in a single ‘finger-prick’ blood sample, and display the results on a handheld analyzer within minutes (Photo courtesy of Philips Healthcare).
The measurement of circulating natriuretic peptides (NP) is considered to be a useful marker of myocardial function, and international guidelines recommend its use for the diagnosis of patients with heart failure (HF), and in particular ruling out the presence of HF.

Point-of-care B-type natriuretic peptide (BNP) testing with adequate analytical performance has the potential to improve patient flow and provide primary care givers with easy-to-use advanced diagnostic tools in the management of heart failure.

An international team of scientists working with the Medical University of Innsbruck (Innsbruck, Austria) performed a comparison with a lab-testing system using samples from 187 patients. Normal values were determined based on 160 healthy adults, (94 males and 66 females; with 84 aged more than 55 years and 76 aged 55 years or less) with ages ranging from 19 to 70 years. Normal values were determined by testing EDTA whole blood and EDTA plasma samples.

The team compared the Minicare BNP with the Siemens ADVIA Centaur BNP, Alere Triage BNP and Abbott I-STAT BNP. The team tested and compared EDTA whole blood samples (on Minicare, Triage and I-STAT) and corresponding EDTA plasma samples (on Minicare and Centaur) from respectively 187 to 216 individuals with a BNP concentration range as measured using Minicare from 10 to 2,890 ng/L.

The scientists reported that the limit of quantitation (LoQ) in whole blood at 20% and 10% coefficient of variation (CV) was found < 9 ng/L and <30 ng/L respectively without significant differences between EDTA whole blood and EDTA plasma. Total CV was found to be from 6.7% to 9.7% for BNP concentrations between 92.6 and 3,984 ng/L. The sample type comparison study demonstrated correlation coefficients between 0.97 and 0.99 with slopes between 1.03 and 1.09 between the different samples. Method comparison between Minicare BNP and Siemens ADVIA Centaur BNP demonstrated a correlation coefficient of 0.92 with a slope of 1.06. The 97.5% upper reference limit (URL) of a healthy population was calculated to be 72.6 ng/L.

The authors concluded that the Minicare BNP assay under development is a fast, robust and sensitive test that can be used in a near-patient setting on capillary or EDTA venous whole blood sample. The Minicare BNP test has the potential for good clinical performance in the diagnosis of HF in various patient settings. The study was published in the May 2019 issue of the journal Practical Laboratory Medicine.

Related Links:
Medical University of Innsbruck

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.